Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery

Inclusion Criteria: * Histological confirmation of breast carcinoma * Histological confirmation of recurrence of chest wall with or without distant metastasis disease * Patients must have failed at least 1 systemic regimen or have clinical stable disease with capecitabine, hormonal therapy (with or without mTOR inhibitor or CDK4/6 inhibitor), or anti HER-2 therapy (trastuzumab, pertuzumab, ado-trastuzumab emtansine, lapatinib) for at least 2 months after their diagnosis of locoregional/metastatic disease * Concurrent radiation therapy is permitted after the study treatment is initiated so long as the planned radiation field doesn't overlap with planned injection sites * Eastern cooperative oncology group performance status (ECOG PS) 0-1 * Absolute neutrophil count (ANC) \>= 1.0 x 10\^9/L; if patient is taking CDK4/6 inhibitor or capecitabine, there is a need for maintaining ANC \>= 1.0 consistently for at least 2 months without dose changes * Platelet count \>= 75 x 10\^9/L, if patient is taking CDK4/6 inhibitor, ado-trastuzumab emtansine or capecitabine, there is a need for maintaining platelet count \>= 75 x 10\^9/L without dose changes * Hemoglobin \>= 8.0 g/L * International normalization ratio (INR) or prothrombin time (PT) 1.5 x upper limit of normal (ULN), unless the subject is receiving anticoagulant therapy, in which case PT and partial thromboplastin time (PTT)/ activated PTT (aPTT) must be within therapeutic range of intended use of anticoagulants * Serum creatini…